Share-Based Compensation (Details) - USD ($)			1 Months Ended		3 Months Ended	9 Months Ended
Share-Based Compensation (Details) - USD ($)	Sep. 30, 2025	Sep. 08, 2025	Mar. 31, 2027	Sep. 30, 2025	Sep. 30, 2025	Sep. 30, 2025
Share-Based Compensation [Line Items]
Stock option granted	54,923			54,923	164,770	164,770
Weighted average remaining vesting period						3 years 11 months 8 days
Consultant grant total options percentage				25.00%
Stock-based compensation expense (in Dollars)					$ 320,125	$ 320,125
Unrecognized stock-based compensation expense (in Dollars)	$ 2,528,619			$ 2,528,619	2,528,619	2,528,619
Unrecognized stock (in Dollars)	$ 112,155			$ 112,155	$ 112,155	$ 112,155
Weighted average grant date fair value per share (in Dollars per share)						$ 2.07
Forecast [Member]
Share-Based Compensation [Line Items]
Stock option granted			54,923
Research and Development Expense [Member]
Share-Based Compensation [Line Items]
Stock-based compensation expense (in Dollars)						$ 78,032
General and Administrative Expense [Member]
Share-Based Compensation [Line Items]
Stock-based compensation expense (in Dollars)						$ 242,093
Vested [Member]
Share-Based Compensation [Line Items]
Grant options vested percentage				25.00%		50.00%
Vested [Member] \| Forecast [Member]
Share-Based Compensation [Line Items]
Grant options vested percentage			25.00%
Stock Options [Member]
Share-Based Compensation [Line Items]
Stock option granted						1,428,006
Stock Options [Member] \| Vested [Member]
Share-Based Compensation [Line Items]
Stock option granted						32,954
Grant options vested percentage						15.00%
Anniversary [Member] \| Vested [Member]
Share-Based Compensation [Line Items]
Stock option granted						43,939
Grant options vested percentage						20.00%
Chief Financial Officer [Member]
Share-Based Compensation [Line Items]
Aggregate grant fair value (in Dollars)						$ 392,500
Aggregate grant expensed percentage						50.00%
Weighted average remaining vesting period						48 months
Requisite service period						48 months
Directors and Officers [Member]
Share-Based Compensation [Line Items]
Stock option granted						1,071,005
Exercise price (in Dollars per share)	$ 4.4			$ 4.4	$ 4.4	$ 4.4
Aggregate grant fair value (in Dollars)						$ 2,231,900
Consultant [Member]
Share-Based Compensation [Line Items]
Stock option granted						219,693
Exercise price (in Dollars per share)	4.4			4.4	4.4	$ 4.4
Aggregate grant fair value (in Dollars)						$ 336,500
Options granted for accounting purposes						1,428,006
Consultant [Member] \| Stock Options [Member]
Share-Based Compensation [Line Items]
Stock option granted						32,954
Aggregate grant expensed percentage						15.00%
Performance Shares [Member]
Share-Based Compensation [Line Items]
Stock option granted						109,846
Maximum [Member] \| Consultant [Member]
Share-Based Compensation [Line Items]
Stock option granted						1,482,929
Minimum [Member] \| Consultant [Member]
Share-Based Compensation [Line Items]
Stock option granted						54,923
Common Stock [Member] \| Stock Options [Member]
Share-Based Compensation [Line Items]
Stock option granted		1,482,929
Exercise price (in Dollars per share)		$ 4.4
Common Stock [Member] \| Chief Financial Officer [Member]
Share-Based Compensation [Line Items]
Stock option granted						192,231
Exercise price (in Dollars per share)	$ 4.4			$ 4.4	$ 4.4	$ 4.4
Deemed Granted [Member]
Share-Based Compensation [Line Items]
Stock option granted						54,923
Consultant grant total options percentage						25.00%

ADAPTIN BIO, INC. 10-Q